Tenaya Therapeutics (TNYA) Share-based Compensation (2020 - 2026)

Tenaya Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 449.0% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 9.21% YoY), and the FY2025 full-year result was $13.0 million, down 20.94% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.2 million, down from $2.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.6 million in Q2 2024, with the low at $400000.0 in Q1 2025.
• Average Share-based Compensation over 5 years is $3.2 million, with a median of $3.5 million recorded in 2023.
• Year-over-year, Share-based Compensation surged 500.0% in 2022 and tumbled 90.53% in 2025.
• Tracing TNYA's Share-based Compensation over 5 years: stood at $3.2 million in 2022, then advanced by 23.91% to $3.9 million in 2023, then dropped by 4.79% to $3.8 million in 2024, then declined by 26.99% to $2.7 million in 2025, then declined by 20.0% to $2.2 million in 2026.
• The last three Share-based Compensation figures came in at $2.2 million (Q1 2026), $2.7 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.

Peer Comparison